Related Experiment Videos
High dose therapy in germ cell tumors: when, what, and how much?
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Neutral Silicon-Vacancy Center in Diamond: Spin Polarization and Lifetimes.
Physical review letters·2017
Medication safety at the interface: evaluating risks associated with discharge prescriptions from mental health hospitals.
Journal of clinical pharmacy and therapeutics·2015
Epigenetics: a new frontier in dentistry.
Australian dental journal·2014
Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis.
Clinical and experimental immunology·2013
Oral health-related quality of life among rural-dwelling indigenous Australians.
Australian dental journal·2010
Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
A multimodal deep learning model for preoperative prediction of post-operative complications in gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026